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Introduction: Despite the decline of tuberculosis in the population at large, healthcare workers (HCW) are still at
risk of infection.
Methods: In a narrative review the TB risk in HCW and preventive measures are described, with the focus on
epidemiology and Occupational Safety and Health (OSH) regulations in Germany.
Results: There is an increased risk of infection not only in pneumology and laboratories with regular contact with
tuberculosis patients or infectious materials. Epidemiological studies have also verified an increased risk of infection
from activities that involve close contact with patients’ breath (e.g. bronchoscopy, intubation) or close contact with
patients in need of care in geriatric medicine or geriatric nursing. In occupational disease claim proceedings on
account of tuberculosis, the burden of proof can be eased for insured persons who work in these or other
comparable fields. Forgoing evidence of an index person as a source of infection has led to a doubling of the rate
of cases of tuberculosis recognised as an occupational disease and has halved the duration of occupational disease
claim proceedings in Germany. For several years now, it has been possible to use the new interferon-y release
assays (IGRAs) to diagnose a latent tuberculosis infection (LTBI) with significantly greater validity than with the
traditional tuberculin skin test (TST). However, variability of the IGRAs around the cut-off poses problems especially
in serial testing of HCWs. At around 10%, LTBI prevalence in German healthcare workers is lower than had been
assumed. It can make sense to treat a recent LTBI in a young healthcare worker so as to prevent progression into
active tuberculosis. If the LTBI is occupational in origin, the provider of statutory accident insurance can cover the
costs of preventive treatment. However, little is known about disease progression in HCWs with positive IGRA sofar.
Conclusion: TB screening in HCWs will remain an important issue in the near future even in low incidence, high
income countries, as active TB in HCWs is often due to workplace exposure. The IGRAs facilitate these screenings.
However, variability of IGRA results in serial testing of HCWs need further investigations.
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Tuberculosis (TB) is the second most frequent work-
related infectious disease among German healthcare
workers (HCW) [1]. Understanding the dynamics of
infection risks for HCWs and developing an adequate
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unless otherwise stated.to protect HCW from TB and to limit the spread of in-
fections from HCWs to patients. In this narrative review
we describe the German perspective and experience with
TB in HCWs. As Germany has an elaborate system for
occupational disease prevention and rehabilitation, tell-
ing the story from a German perspective might encour-
age other countries with less developed OSH systems [2]
to improve infection control in HCWs.Epidemiology of tuberculosis in Germany
According to information provided by the Robert Koch
Institute (RKI), in 2011 a total of 4,317 cases of tubercu-
losis were registered in Germany (previous year: 4,388),al Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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cases per 100,000 inhabitants [3]. The clear downward
trend observed in Germany in recent years thus almost
ground to a halt (Figure 1). The lung was the organ most
frequently affected by TB, accounting 79.6% (3,346) of
cases. Around one third (33.9%) of lung tuberculosis were
of the infectious, microscopically positive type. The suc-
cess of treatment in higher age groups declined continu-
ously to just 63.3% in patients aged 70 and over. The
incidence of TB among citizens with a migration back-
ground is approximately four times higher than among
German nationals (5.3 versus 21.5/100,000).
Transmission paths and clinical picture of TB
Bacteria of the Mycobacterium tuberculosis (MTB) com-
plex are transmitted from person to person by droplet
infection and rarely via smear infections on skin and
mucous membranes, via contaminated dust particles or
cuts and stab wounds involving contaminated cannulae
or scalpels [4]. Environmental factors, hygiene condi-
tions, the amount of germs discharged and the virulence
of the pathogens determine the degree of infection risk.
Personal factors such as nutritional condition, age, im-
mune status and comorbidity determine susceptibility of
infection and the progression of the disease.
Primary tuberculosis or latent TB infection (LTBI)
The risk of infection increases with the duration and
closeness of contact with the source of infection. How-
ever, brief occasional contacts – even a single conversa-
tional contact – can also lead to infection [5]. After an
incubation period of five to six weeks on average (max-
imum 8 weeks), an inflammatory reaction occurs in the
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Figure 1 Incidence of TB in Germany in the years 2000 to 2011 [3].nodes (primary complex). In most cases, this process
heals without significant clinical symptoms. Sometimes
calcification takes place, so that the primary focus and
possibly also the associated lymph nodes remain radio-
logically identifiable at a later date (Ghon foci). However,
it is also possible that active tuberculosis will develop
immediately, with a progressive, infiltrative and cavitat-
ing process and/or with bronchogenic, haematogenous
or lymphogenous spread, leading to further organ
manifestations.
In the primary complex, which often cannot be rendered
visible, viable mycobacteria capable of replication and pro-
liferation may remain for years or decades. This leads to
sensitisation of monocytes circulating in the peripheral
blood. The presence of these sensitised monocytes can be
measured by means of a tuberculin skin test (TST) or with
the interferon-y release assays (IGRAs) that have recently
become available. Both tests are based on the cell-
mediated immune response to M. tuberculosis antigens.
However, the IGRA is considerably more specific than the
TST, since it works with only two or three M. tuberculosis
antigens instead of approximately 200 antigens as in the
tuberculin for the TST [6,7]. Therefore, a positive TST
should be validated by an IGRA so as to rule out non-
specific reactions, e.g. to a Bacillus Calmette-Guerin
(BCG) vaccination or to environmental non-tuberculous
mycobacteria (NTM). Two different IGRAs are commer-
cially available, the ELISA-based QuantiFERON-TB Gold
In-Tube® and the ELISPOT-based T-SPOT.TB®.
Since IGRAs are in vitro tests, the problem of boosting
that occurs in serial testing with TST is avoided. The
IGRA correlates better than the TST with exposure to
infectious patients and shows higher sensitivity to active
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contact to infectious patients in low-incidence countries
as regards the progression of the disease [10,11]. Even
though only one study reported progression risk in
HCWs based on four cases [11], IGRAs are likely to im-
prove both the effectiveness and the efficiency of TB
screening in HCWs [12]. However, as yet no consensus
exists on the interpretation of IGRA results in serial test-
ing [6,7,13]. In serial testing especially, it is important to
state IGRA results not only qualitatively but also
quantitatively.
Some more water needs to be purred into the wine. As
IGRA are not able to distinguish LTBI from active TB,
IGRA are no reliable test for the diagnosis of active
TB [14].
A conversion – when a previously negative test result
becomes positive when measured again – indicates a
fresh infection with M. tuberculosis. Reversion of im-
munological tests from positive to negative is possible if
MTB is successfully eliminated (transient infection) or if
there is so little MTB activity in the primary complex
that T-cells are no longer sensitised [15].
Post-primary tuberculosis
In the generalisation phase, the mycobacteria spread
through the blood or lymph, developing a focus in the
lung or other organs. Initially, this is usually silent. If
such foci are reactivated – in the lungs, usually in the
apex area – active tuberculosis of the lung, or for ex-
ample of the kidney, genitals or bone, may develop
months or even decades later, requiring treatment. As
mentioned above, around one-third of new cases are
extra-pulmonary [3]. These forms of tuberculosis result
from the reactivation of primary tuberculosis, or may be
caused by re-infection.
Diagnosis
Diagnosing TB is sometimes difficult due to the diverse
forms of manifestation. In addition, diagnosis is often be-
lated because there are no specific symptoms and the possi-
bility of TB is too rarely considered in differential diagnosis.
Symptoms or circumstances that indicate the presence
of TB are:
 Clinical symptoms such as coughs, phlegm, weight
loss, tiredness, nocturnal sweating, fever, breathing-
dependent pain in the thorax
 Tuberculosis in the anamnesis
 Occupational or private exposure to tuberculosis
 Positive interferon-y release assay (IGRA)
 X-ray results raising suspicion of tuberculosis
The diagnosis is confirmed by evidence of tuberculosis
pathogens in test materials such as sputum, bronchialsecretions, gastric juice, urine or pus from an abscess.
The quickest method is microscopic examination. How-
ever, this is crude and only shows positive results at
approx. 104–105 bacteria/ml of material. Since only acid-
fast bacilli (AFB) can be verified under the microscope,
the diagnosis of TB is not confirmed. Only a positive
culture confirms TB. Cultural verification is possible
with only around 50–100 bacteria/ml in the test mater-
ial. Alternatively, TB can be confirmed by molecular
biology methods (e.g. polymerase chain reaction, PCR)
to verify TB-specific DNA or RNA.
Welcome progress has been made in developing these
methods further in recent years. In an attempt to create
an easy-to-use, low-cost test, the Xpert MTB/RIF system
has become prevalent. The WHO has been recommend-
ing the use of the test since 2010 for initial diagnosis
where tuberculosis is suspected, primarily in high-
prevalence countries with a high proportion of HIV
patients and where multi-drug-resistant (MDR) tubercu-
losis is suspected. The Xpert MTB/RIF offers a fully
automatic real-time PCR for M. tuberculosis complex-
specific DNA and a sub-unit of bacterial RNA polymer-
ase beta (rpoB), which is observed in 95% of resistance
to Rifampicin. It is easy to handle and takes about 20 mi-
nutes of active work, with a result available in two hours.
Admittedly, the Xpert MTB/RIF is not sensitive enough
to be the sole method used in developed countries. The
role of Xpert MTB/RIF in the diagnosis of TB in high in-
come, low TB incidence countries is currently under
study [16].
Risk factors for tuberculosis
The WHO assumes that 30% of the world’s population is
infected with M. tuberculosis. These latent TB infections
(LTBIs) lead to active TB in 10% of those affected during
the course of their lives. In around half, active TB develops
within the first two years after infection. Children are
more likely than adults to develop active TB after infection
(around 30%) [10]. Malnutrition, homelessness and alco-
holism, along with HIV infection and other diseases that
weaken the immune system, or immunosuppressive ther-
apies (in which TNF-alpha blockers are especially signifi-
cant) are typical risk factors for activation of LTBI.
It was previously assumed that in countries with a low
incidence of TB most cases of active tuberculosis result
from reactivation of an LTBI. However, infection epi-
demiology findings from cluster analyses using finger-
printing to differentiate between strains suggest that new
infections in developed countries may account for up to
40% of active tuberculosis cases [17,18], rather than 10%
as had been previously assumed [19]. An LTBI or active
TB in the anamnesis does not protect against reinfec-
tion. Depending on the country and study, reinfections
are responsible for 10% to 75% of all second episodes of
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geted prevention measures can significantly reduce
transmissions of M. tuberculosis [21,22].
Tuberculosis risks in healthcare
Healthcare workers are at increased risk of LTBI and ac-
tive tuberculosis [22-25]. However, in countries with a
low incidence of TB, it can be difficult to verify this in-
creased risk of infection since the customary risk factors
for both infection and for active TB are less prevalent
than among the general population, and not all health-
care workers have contact with TB patients. Moreover,
appropriate preventive action (see below) can be taken
to minimise the risk of infection when caring for pa-
tients known to be suffering from tuberculosis [24].
Fingerprinting and the supplementary molecular biology
methods for differentiating between strains of M. tubercu-
losis improve the possibility of discovering infection path-
ways. Individuals with different strains of TB cannot have
infected each other. Individuals with the same strain of TB
may be part of a common infection pathway. In molecular
epidemiology, patients with the same strain of TB are
known as clusters (Figure 2). However, belonging to a
cluster cannot be equated with confirmed transmission of
TB. Rather, an appropriate infectious contact needs to be
ascertained as probable by interviewing the members of
the cluster. Three molecular epidemiology studies on the
occupational risk of infection have been published so
far [4,26,27].
In the Hamburg fingerprint study [4], mycobacteria cul-
tures have been used continuously since 1997 to generate
fingerprints of all individuals with notifiable TB. The study
covers 848 cases where IS6110 fingerprinting was carried
out. Ten study participants with TB were healthcare
workers. Through fingerprinting and a subsequent survey,
it was possible to prove occupation-related transmission
in eight of those individuals. Thus the proportion of
occupation-related tuberculosis in healthcare workers was
80% (95%CI 44%–97%). Of eight occupation-related trans-
missions, six were unknown prior to fingerprinting.
A fingerprint study on the infection risk among
healthcare workers in the Netherlands found that in 28
out of 67 (43%) persons with active TB, transmission
from patient to staff was proved [26]. The main reason







Figure 2 Example of two identical fingerprints from the Hamburg finespecially among older patients. Ten (out of 28) index
cases were older people with comorbidity whose tubercu-
losis had not been diagnosed promptly, as a result of
which no appropriate preventive measures had been
taken.
The most up-to-date molecular epidemiology study on
the occupational infection risk included all TB cases re-
ported in San Francisco from 1993 to 2003 [27]. In all,
there were 2,510 TB cases. Fingerprinting was then per-
formed for 1,852 patients. Thirty-one patients (1.2% of
the total) were healthcare workers. Occupationally re-
lated TB was confirmed in ten (32%) of the 31 health-
care workers.LTBI prevalence in healthcare workers
LTBI is assumed when the IGRA is positive and active TB
is excluded by X-ray. In German HCWs LTBI prevalence
depends on the age of employees. It increases from 2.6%
among the under-25 s to 22.2% among the over-55 s
(Table 1) [28-31]. The prevalence of LTBI is the same for
men and women. The reason for investigation pursuant to
the German regulation on occupational healthcare provi-
sions (ArbMedVV) (see below) also has no influence on
the prevalence of LTBI. Likewise, there are no differences
between doctors and nurses. LTBI prevalence is higher
among geriatric care nurses, otherwise no differences were
described between the different occupational groups and
activities in Germany [29-31]. About 15% of German
HCWs are foreign born and their prevalence of LTBI is
more than two times higher than in German born
HCWs [30].
LTBI prevalence among healthcare workers in Germany
is considerably lower than had been assumed on the basis
of studies based on TST [29]. Moreover, the prevalence of
LTBI in Germany is significantly lower than in France or
Portugal (10%, 19%, 33%) [32,33]. As yet, no comparative
data on the prevalence of LTBI in the unaffected popula-
tion is available for Germany.Prevention of tuberculosis
The most effective measures for preventing TB infection
are early identification of cases and isolation. It is there-
fore important for hospitals to consider the possibility of




Table 1 Latent TB infections (positive IGRA) among
healthcare workers according to the German TB network
of occupational health physicians, following [28-31]







< 25 years 494 (12.9) 481 (97.4) 13 (2.6)
25-35 years 926 (24.2) 878 (94.8) 48 (5.2)
35-45 years 1,057 (27.6) 982 (92.9) 75 (7.1)
45-55 years 974 (25.5) 867 (89.0) 107 (11.0)
>55 years 372 (9.7) 297(79.8) 75 (20.2)
Gender
Female 2,959 (77.4) 2,716 (91.8) 243 (8.2)
Male 864 (22.6) 789 (91.3) 75 (8.7)
Reason for screening
Regular contact with TB patients
or infectious material (obligatory)
2,533 (66.3) 2,310 (91.2) 223 (8.8)
Contact tracing (optional) 1,290 (33.7) 1,195 (92.6) 95 (7.4)
Profession
Physician 583 (15.2) 538 (92.3) 45 (7.7)
Nurse 1,962 (51.3) 1,804 (91.9) 158 (8.1)
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preventive chemotherapy [34].
Table 2 summarises the main protective measures for ef-
fective control of tuberculosis in the clinical field. Various
studies proved that implementing these measures to pre-
vent infection contributes substantially toward reducing the
risk for healthcare workers [34-36]. However, it is not pos-
sible to make any specific deductions as to the significance
of individual sub-aspects. Clearly, organisational and
administrative measures are very important, followedTable 2 Tuberculosis prevention measures in the
inpatient sector, following [35]
Organisational/administrative
measures
- Early establishment of a diagnosis
- Isolation
- Early initiation of appropriate
therapy
Patient - Information and clarification
- Cough hygiene
- Mouth and nose protection
Employee - General hygiene
- Respiratory protection
- If necessary, protective clothing
- Education and training
- Operational monitoring
Workplace - Correct room ventilation
- Suitable disinfectionby technical and individual preventive measures. Ul-
timately, only the interaction of various preventive mea-
sures can reduce the risk of infection to a minimum.
Isolation
The decision whether to isolate must be made on a
case-by-case basis. Isolation is indicated as a matter of
principle when open, and therefore infectious, tubercu-
losis of the respiratory tract is suspected or confirmed.
The decision whether to isolate patients with negative
sputum microscopy must be made individually. Isolation
in special tuberculosis wards is not necessary, but the
patient should be in a single room. Cohort isolation
should only be effected when direct infection chains are
assumed (e.g. mother–child). Tests and transfers to
other departments for diagnostic or therapeutic pur-
poses that can be postponed should be deferred if pos-
sible until the patient can be assumed to be no longer
infectious.
As a rule, isolation measures are not necessary in cases
of extrapulmonary tuberculosis, though infectious ma-
terial must be treated with appropriate caution [37].
The decision whether to discontinue isolation depends
primarily on the microscopically verifiable decrease in
the secretion of pathogens in sputum and on the clinical
and radiological response to therapy. Three microscopic-
ally negative sputum results are necessary. In most cases,
sputum conversion takes place three weeks after the
start of an effective therapy. In individual cases (cavern-
ous processes, absence of bacteriological and/or clinical
evidence that therapy has been successful, drug resist-
ance, immunosuppression, lack of compliance), however,
a longer period of isolation may be necessary. In such
cases, the date for ceasing isolation must be determined
individually. Decisions on the need for treatment as an
inpatient must be taken individually, taking into account
factors such as the severity of the tuberculosis, under-
lying diseases or comorbidity, problems with therapy
and patient cooperation. If the appropriate framework
conditions are in place (medical care, patient reliability,
home circumstances), clinically stable tuberculosis pa-
tients can be treated as outpatients [37].
Therapy adherence
The most important prerequisite for treatment to suc-
ceed is reliable, regular intake of anti-tuberculosis drugs.
This must be properly explained to patients. They must
be told in understandable terms why tuberculosis must
be treated with a combination of drugs for such a long
time. If reliable intake of medication is not assured or is
in doubt, the treatment must be supervised directly
(DOT = directly observed treatment). As a matter of
principle, medicines must be taken under supervision
during a stay in hospital.
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trol of Infectious Diseases Act (Infektionsschutzgesetz,
IfSG) to notify refusal or premature withdrawal from
treatment is intended to facilitate the identification of pa-
tients in need of active support and possibly also close
supervision during their treatment.
General hygiene
Patients must be encouraged to adopt hygienic behav-
iour (coughing into a paper handkerchief, turning away
from other people) and to wear a mask over mouth and
nose. In a recent study, it was shown for the first time
that the MTB concentration in the air of the patient’s
room is lower if the patient wears a mask [38]. When
contamination of the hands with pathogen-containing
material is to be feared (e.g. during oral hygiene, aspir-
ation, catheter maintenance and urine disposal in tuber-
culosis of the urinary tract, and bandage changing or
wound dressing when skin secretions contain patho-
gens), personnel must wear protective gloves and, in the
event of aerosol-generating procedures, a respirator
mask (see below). Personnel at risk, fellow patients and
other contact persons must be given detailed, under-
standable instructions about possible paths of infection
and the necessary protective measures.
Ventilation
Adequate ventilation of rooms where infectious tubercu-
losis patients are accommodated is of crucial import-
ance, as it helps to dilute or eliminate infectious aerosols
and minimise the further spread of germs into the envir-
onment (no recirculation of air containing bacteria, air
flow towards the patient’s room and from there to out-
side) [34,36,39]. If a ventilating and air-conditioning sys-
tem (with negative air pressure in the isolation room
and positive air pressure in the anteroom) is used, there
should be a change of air at least four to six times per
hour. Some authors call for a frequency of nine to twelve
times an hour. No scientific arguments could be found
for a precise minimum frequency of air change [35].
Respiratory protection
There is no evidence-based proof of the effectiveness of
respiratory masks in preventing M. tuberculosis infec-
tion. Given that diagnosis, therapy, and the control and
infection prevention measures outlined above already
significantly reduce the risk of transmission via known
or suspected tuberculosis cases, respiratory masks make
a limited contribution toward risk reduction. However,
where there is exposure to higher concentrations of
aerosols, it makes sense to wear one.
Like the masks worn in industry, better fitting,
particle-filtering half masks with improved filtration are
available for medical needs (filtering face piece = FFP).The FFPs currently available are classified according to
European standards (EN 149). The total leakage from a
mask is made up of leakages around the face, leakage
around the exhalation valve (if there is one) and leakage
from the actual filter penetration. The average total leak-
age for Class 1 respiratory masks must not exceed 22%
under test conditions. That of Class 2 masks must not
exceed 8% and Class 3 must not exceed 2% (with an
average particle diameter of 0.6 μm). FFP2 masks (or
equivalent) are recommended as a personal protective
measure for preventing infection in case of tuberculosis.
The wearer must be instructed and the fit must be
checked, as the protective effect of the respirator can only
be reliable if it fits properly and is used correctly [40].
In the presence of other persons, patients should wear
at least conventional mouth and nose covering masks
inside and always outside the isolation room so as to
reduce the spread of aerosol (see above).
In order to ascertain the need for personnel to use re-
spiratory masks, a risk analysis should be undertaken for
the relevant institution or relevant department and the
specific patient. FFP2 masks are used either where
exposure to the coughing of patients suffering from sus-
pected or confirmed open tuberculosis is unavoidable, or
where a high concentration of aerosol must be assumed.
In special situations, a specific risk assessment must be
carried out to identify suitable respiratory protection.
Disinfection and sterilisation
Thermal disinfection is always preferable to chemical
disinfection, as it is safer, more reliable (inter alia be-
cause of the possibility of automation) and less harmful
(allergies resulting from chemical disinfectants, environ-
mental pollution). Industry has developed devices for
different fields of medicine that enable thermal disinfec-
tion of a variety of instruments, respiratory accessories,
etc. [37].
Surfaces should be disinfected by standard hygienic
methods. Spray disinfection is not sufficiently effective.
Although microorganisms, and thus also tuberculosis
bacteria, can be detected on surfaces such as walls,
floors and furniture, they are very rarely a real infection
risk for humans because no aerosols are formed.
Special disinfection of urine or stool is not necessary.
If pathogen-containing excretions are collected, they can
be disposed of by thermal disinfection (with customary
cleaning and disinfection equipment).
Disinfectant cleaning of surfaces that may be contami-
nated with pathogen-containing particles should also be
carried out in the home. Clothing should be washed at a
minimum of 60°C with customary laundry detergents
and carpets should be cleaned to remove dust particles
as far as possible, if need be by spray extraction. The
spraying of formaldehyde is no longer permitted.
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Contact tracings by health authorities pursuant to IfSG
serve to identify at an early stage cases of TB and indi-
viduals who can benefit from preventive chemotherapy.
TB screening by occupational health physicians serves
the same purpose.
As the TB incidence in Germany decreased over recent
decades (Figure 1), in order to avoid unnecessary X-ray ex-
aminations due to a false positive TB test there was a para-
digm shift to optional checks as warranted by accidental
occupational exposure to M. tuberculosis. According to
the German regulation on occupational healthcare provi-
sions (ArbMedVV), employees must be offered tests ‘if as
a result of exposure to biological agents a serious infection
or disease can be expected and post-exposure prophylactic
(prevention) measures are possible’. This applies to TB.
In contrast, obligatory checks pursuant to the Arb-
MedVV are only provided for in the case of employees
in tuberculosis departments and other pneumological fa-
cilities or research institutes and laboratories who have
regular contact with infectious patients or materials. If
regular obligatory checks are performed, there is no
need for an additional test after unprotected contact
with an infectious patient or infectious materials.
Participation in an optional check or obligatory occu-
pational health check in accordance with ArbMedVV re-
places contact investigations pursuant to IfSG. In order
to avoid duplicate tests, it makes sense for occupational
health physicians to conduct their tests in consultation
with public health authorities and to use the appropriate
formula for checks as per the German Central Commit-
tee to Combat Tuberculosis (Deutsches Zentralkomitee
zur Bekämpfung der Tuberkulose, DZK) recommenda-
tion for contact investigations [5]. If an employee fails
take up the option of a test, the local public health au-
thority is responsible for performing the contact investi-
gation in accordance with IfSG.
The aim of TB screenings is to identify employees with
a recent LTBI, as they will benefit most from preventive
chemotherapy. It is therefore not expedient to examine
all possible contact persons. Instead, only ‘close contact
persons’ should be tested, as the proportion of recent in-
fections among them will be higher in close contacts.
The probability of transmission depends on the patient’s
infectiousness (microscopically positive or negative), prox-
imity to the infectious source, and the duration of contact.
This suggests the following criteria for selecting contact
persons [5]:
A) brief but intensive contact with a coughing, sputum-
positive patient without protection,
B) cumulative contact duration of at least eight hours
with a patient with microscopic evidence of AFB in
a direct specimen of sputum,C) cumulative contact duration of at least 40 hours
with a patient with only culturally or molecular
biologically confirmed evidence of tuberculosis.
In practice, this rule is often difficult to apply because
the contact duration cannot be reliably estimated or be-
cause uncertainty among employees may lead them to
want a check-up. Hence the above-mentioned criteria
should be seen only as guides to the selection of contact
persons.
In the case of optional checks, an IGRA should be car-
ried out only eight weeks after the last contact with the
index patient or the infectious materials, so as to leave
sufficient time for the immunological reaction to de-
velop. A chest X-ray after a positive IGRA should be
done only three months after the last contact with the
possible source of infection, since development of active
TB is unlikely before then. The flow chart below is based
on the recommendations for contact investigations [5].
Preventive check-ups in accordance with ArbMedVV
are repeated regularly (obligatory test) or as warranted
after unprotected contact. This raises the question how
different IGRA results in serial tests are to be inter-
preted. The variability of IGRA in serial tests is not yet
sufficiently understood [6,13,41]. Reversion of positive
IGRA results into negative results is more frequent than
conversion of negative IGRA results into positive ones.
More significant is the fact that the probability of con-
version or reversion depends on the quantitative test re-
sults of the first IGRA. Thus a grey area could be helpful
in separating genuine conversions and reversions and
chance deviations. The Center for Disease Control and
Prevention (CDC) and the European Centre for Disease
Prevention and Control have proposed a grey area in the
range 5–7 spot forming cells (SFC) for T-SPOT.TB [42].
As yet, however, no consensus has been reached on a
grey area for QuantiFERON-TB Gold In-Tube (QFT). A
grey area of 0.2 and 0.7 IU/mL and defining conversion
and reversion as overstepping this grey area minimise
the rate of conversion and reversion and keep the pro-
portion of employees whose QFT values are within this
grey area relatively low [43-45].
Since the reversion rate with IGRA is higher than ex-
pected [6,13], ‘once positive, always positive’, the statement
that used to apply to TST, is obsolete. All healthcare
workers should be re-tested with the IGRA in a planned
routine screening. This reduces the number of chest X-
rays needed, since no further medical check is necessary if
the IGRA reverts to negative and there are no recognis-
able clinical signs of active TB. Chemoprevention (see
below) in employees with fluctuating test results requires
further discussion. Assuming that recent exposure to M.
tuberculosis is probable, the simplest approach would be
to rule out lung tuberculosis if the IGRA result is positive
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the test result is negative and there are no recognisable
clinical symptoms of tuberculosis. The same applies to
employees with results in the grey area. If they have no
clinical symptoms, no further medical examination is ne-
cessary. However, more data on progression to the disease
is needed in order to deduce evidence-based recommen-
dations for chemotherapy treatment for employees with
an IGRA conversion or reversion, and for employees with
IGRA results in the grey area.
Employees whose anamnesis includes chemotherapy for
LTBI or those with repeat positive IGRA results should
not be re-tested in subsequent preventive checks since the
IGRA results would not be revealing. If one of these em-
ployees is part of a cohort with a low risk of progression
(e.g. no active tuberculosis among hospital personnel in
recent years), a chest X-ray should only be taken if there
are suspicious clinical symptoms. Figure 3 shows a deci-
sion tree for repeat preventive checks for healthcare
workers in accordance with ArbMedVV. However, it
should be noted that further research is needed to prove
the usefulness of this approach in countries with low TB
incidence and high hygiene standards [46]. Furthermore it
needs to be pointed out that this recommendation seems
helpful for countries like Germany with currently low TB
incidence but history of highTB incidence and high preva-
lence of BCG vaccination in HCWs. In countries with a
long history of low TB incidence and no BCG vaccination
policy and therefore low rates of positive TST results in
HCWs other conclusions might be drawn as is shown
in the Canadian recommendations. In Canada for serialFigure 3 Decision tree for repeated IGRA according to [46].testing of HCWs the TST is recommended because com-
pared to TST unexplained variability of the IGRA seems
to be higher [47,48].
Chemoprevention
The probability of developing active TB during the first
two years following a positive IGRA is significantly lower
for healthcare workers than for close contacts in the gen-
eral population [10,11]. This can probably be explained by
the fact that healthcare workers do not have the typical
risk factors for developing active TB (alcoholism, home-
lessness, etc.) and that a positive IGRA in healthcare
workers is often caused by an remote LTBI with a low risk
of progression. This should be taken into account when
selecting individuals to be treated with preventive chemo-
therapy. Chemoprevention should only be considered if
the employee is under 50 and the IGRA is positive after
recent exposure to M. tuberculosis [5].
Before initiating chemoprevention, a chest X-ray must
be taken to rule out active TB and a further check must
be carried out after completing chemoprevention so as
not to overlook a disease that may be developing despite
chemoprevention.
Chemoprevention involves taking Isoniazid (INH)
300 mg daily for six or preferably nine months. This ther-
apy for the treatment of LTBI can achieve 90% protection
[49]. In practice, however, effectiveness is significantly
lower, mainly because of insufficiently regular intake of
the medication for this long period.
If the MTB of the index case is resistant to INH, or
the contact (i.e. the HCW) is unable to tolerate INH, as
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for four months, or a combination of INH and RMP for
three to four months for chemoprevention [50]. How-
ever, the effectiveness of these two alternatives has been
less well researched.Hepatotoxicity of chemoprevention with INH
Acceptance of chemoprevention is reduced by the fear
of possible liver damage. Until now, only two meta-
analyses have dealt with the number of INH-induced
hepatitis in adults. According to these analyses, the
probability of INH-associated hepatitis is 0.6%. Occa-
sionally, however, significantly higher rates of up to 5%
were described [49,51]. Because of the hepatotoxic side
effect of INH, regular laboratory controls (after two and
four weeks, then monthly) are necessary. If there is a sig-
nificantly raised level of liver enzymes, chemoprevention
should be discontinued.New treatment regime in chemotherapy
Significantly shorter treatment periods and considerably
fewer tablets than with previous offers are the key ele-
ments for improving the results of preventive treatment
in persons with freshly diagnosed LTBI. Two recently
published, extensive and randomly controlled studies
provide evidence that the combined therapy of INH and
Rifapentin (RPT) administered once a week for twelve
weeks is less toxic than classic INH therapy and equally
effective [52,53]. In the United States, therefore, the
CDC recommends this combination therapy [54].
Should the new regime become established, this will
make it considerably easier for occupational health phy-
sicians to advise chemoprevention and further reduce
the number of healthcare workers requiring treatment
for TB at a later date.Table 3 Activities categorised by infection risk according to [
Category A Category B
Activity, Area
TB ward, specialist lung clinic,
specialist lung doctors, micro-
biology laboratories that examine
sputum
Bronchoscopies, laryngoscopy, emerge
intubation, post mortems, work in infec
wards, emergency services, A & E, geria
and geriatric care*, looking after at-risk
groups, deployment abroad in areas w
high incidence
Easing of burden of proof
Yes, index not necessary Yes, index not necessary
Reasons
Infection risk due to particular
patients or materials
Infection risk proven by epidemiologica
studies
*If there is close contact with patients in need of care.Tuberculosis as an occupational disease in Germany
Unlike in other European countries such as France [55], it
is not generally assumed in Germany that healthcare
workers with patient contact run a greater risk of TB in-
fection, and therefore of contracting the disease. There-
fore, according to number 3101 of the German Ordinance
on Occupational Diseases (Berufskrankheitenverordnung,
BKV), tuberculosis in a healthcare worker can only be
recognised as an occupational disease if an increased oc-
cupational risk of infection can be proven and if there is
no (competing) risk of infection outside work [56]. Ac-
cording to BKV, both tuberculosis in HCWs and silico-
tuberculosis in workers exposed to silica dust can be
recognised as occupational diseases. Furthermore, active
TB as the result of an accident can be compensated by
statutory accident insurance schemes. In addition to work
postings to countries with a high incidence of TB, this is
also relevant in the case of occupational exposure to M.
tuberculosis, i.e. contact to a college with active TB outside
the healthcare sector. Transmission of M. tuberculosis can
be considered an accident as it takes place within 24 hours,
the juridical definition for the relationship of cause and
effect in the realm of the social accident insurance legisla-
tion in Germany.
As shown in Table 3, in addition to close contact with a
known index person (infectious patient), healthcare
workers run an increased risk of infection from work in
specialist lung clinics and laboratories (Category A) if they
regularly come into contact with tuberculosis patients or
sputum samples. However, a raised risk of infection can
also be explained epidemiologically (Category B) [25,31].
There is a special risk from unknown, or belatedly
recognised, tuberculosis. Often, but not necessarily, Cat-
egory B activities are associated with close contact with
the air the patient exhales (bronchoscopy, intubation,
extubation, etc.). An increased risk of infection may also
arise if once in a while tuberculosis patients are51]
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Even if it is out of the question that the known patient is
the index person, e.g. because there was no personal
contact with the particular patient, in such institutions
one can expect the rate of unrecognised TB cases in this
group of patients to be higher than in the population at
large. Typical institutions are e.g. general practices and
general hospitals without infection wards.
Category D includes institutions where there is no in-
dication of an increased rate of tuberculosis among pa-
tients. This category includes all institutions that do not
fall under Category A to C, such as dermatologists, sur-
geons (except chest surgeons), rehab clinics, psychother-
apy practices and physiotherapists (as long as they do
not carry out respiration therapy).
In assessing the circumstances in occupational disease
claim proceedings there is no need to look for an index
person in Categories A and B. Instead, the typical clien-
tele of patients (Category A) or epidemiological data
(Category B) make it easier to find proof. In Category C
it is possible to recognise the causal links even if no
index person could be found. However, judgement must
be passed on a case-by-case basis. No general statement
can be made as to the number of TB cases per year from
which there is an increased risk of infection. In Category
D, recognition as an occupational disease is only possible
if a plausible index person can be identified.
Since the publication of the new recognition criteria
for the first time in 2003 [56], there has been a rise both
in the number of tuberculosis cases reported and in the
number recognised as occupational diseases at the Insti-
tute for Statutory Accident Insurance and Prevention in
the Health and Welfare Services (Berufsgenossenschaftfür Gesundheitsdienst und Wohlfahrtspflege, BGW)
(Figure 4). In 2000, 24 HCWs with tuberculosis were
recognised as having an occupational disease. In 2012,
the number was 66. The rate of recognition among the
decided claims rose from 18% in 2000 to 45% in 2012.
Since the risk of infection in the healthcare sector has
not risen in recent years, one can assume that the in-
crease in tuberculosis as an occupational disease is at-
tributable to the extension of criteria that ease the
burden of proof. An analysis of 150 expert opinions in
claim proceedings cases found that it had been recom-
mended that the burden of proof be eased in every sec-
ond case (52%). Easing the burden of proof has halved
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ings in Germany [56].
In addition to active tuberculosis, an LTBI can be re-
ported as an occupational disease. The number of LTBIs
reported as occupational diseases has risen significantly
in the last few years (Figure 5). This increase, too, can-
not be explained by an increase in the risk of infection
in recent years. Rather, the increased reporting is based
on the fact that for some years the above-mentioned
IGRA has rendered the diagnosis of LTBI more valid in
a population of HCWs with a high prevalence of BCG
vaccination. It makes sense to report LTBI as an occupa-
tional disease especially if preventive chemotherapy is
being considered. Preventive chemotherapy makes sense
if a young healthcare worker (e.g. below the age of 35)
has a positive IGRA eight weeks after close contact with
a microscopically positive patient (see above). In this
case, it is probable that the cause of the LTBI was occu-
pational. There is no need for laborious investigations in
occupational disease claim proceedings and the costs of
consultation with and treatment by a pneumologist can
be paid by the statutory accident insurance scheme
under Paragraph 3 (Prevention) of the Ordinance on Oc-
cupational Diseases (BKV).
Conclusion
TB in HCW and nosocomial transmission of TB will re-
main a challenge for OSH experts as the downward trend
in TB incidence in the general population has seemingly
come to a halt and the TB incidence in migrants is still
high in Germany. Furthermore, the pool of LTBI in HCW
is large, especially in those who started work during the
decades when TB incidence in Germany was higher.
IGRAs allow for a better assessment of the infection risk
than TSTs. However, they do not permit a distinction be-
tween remote and recent infection. Therefore evaluation
of recent exposure remains important when choosing the
target group for preventive treatment. Variability of IGRA
results is not jet well understood and we need epidemio-
logic studies in order to decide the most effective and effi-
cient screening strategy in HCWs.
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